Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Breast 24Gastrointestinal 18Thoracic 17Genitourinary 15CNS 11Tumor-Agnostic 8Dermatologic 8Gynecologic 7Lymphoid 6Head & Neck 6Other hematologic neoplasm 5Myeloid 5Other solid neoplasm 4Sarcoma 3Endocrine 3Classical hematology 2Plasma cell 1NET 1

Conditions

Pituitary Neoplasms 1Neuroendocrine Tumors 1High Grade Neuroendocrine Neoplasms 1Brain Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 15Specimen Handling 14lutetium Lu 177 dotatate 13Nivolumab 11cabozantinib 10Everolimus 9pembrolizumab 8gallium Ga 68 dotatate 7Ipilimumab 6Cisplatin 6Carboplatin 6Etoposide 5trametinib 4olaparib 4lenvatinib 4X-Rays 4Lutetium-177 4CTLA-4 Antigen 4fluorodopa F 18 3dabrafenib 3cemiplimab 3Surveys and Questionnaires 3Phantoms, Imaging 3Immunoglobulin G 3Fluorodeoxyglucose F18 3Disulfides 3Cyclophosphamide 3Blood Specimen Collection 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3selpercatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Blood Specimen Collection × Endocrine × 90 days × Clear all
NCT06430021 2026-05-22

PRO-NEM1

Centre Hospitalier Universitaire Dijon

Recruiting
297 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT03465618 2026-05-01

A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors

Memorial Sloan Kettering Cancer Center

Phase 1 Active not recruiting
17 enrolled
CNSEndocrine

Brain Neoplasms, Pituitary Neoplasms

NCT04412629 2026-04-06

Cabozantinib in High Grade Neuroendocrine Neoplasms

Washington University School of Medicine

Phase 2 Active not recruiting
35 enrolled
Endocrine

High Grade Neuroendocrine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡